scholarly journals Vancomycin Dosage Regimens for Pediatric Patients

2009 ◽  
Vol 14 (2) ◽  
pp. 64-65
Author(s):  
Milap C. Nahata
2020 ◽  
Vol Volume 13 ◽  
pp. 685-695
Author(s):  
Sooyoung Shin ◽  
Hyun Joo Jung ◽  
Sang-Min Jeon ◽  
Young-Joon Park ◽  
Jung-Woo Chae ◽  
...  

1990 ◽  
Vol 34 (6) ◽  
pp. 1165-1171 ◽  
Author(s):  
A K Hurst ◽  
M A Yoshinaga ◽  
G H Mitani ◽  
K A Foo ◽  
R W Jelliffe ◽  
...  

2002 ◽  
Vol 25 (10) ◽  
pp. 1333-1338 ◽  
Author(s):  
Hitomi Teramachi ◽  
Hiromi Hatakeyama ◽  
Ryo Matsushita ◽  
Yukio Imai ◽  
Ken'ichi Miyamoto ◽  
...  

2015 ◽  
Vol 20 (6) ◽  
pp. 418-430 ◽  
Author(s):  
Amber Thomas ◽  
Jamie L. Miller ◽  
Kevin Couloures ◽  
Peter N. Johnson

OBJECTIVES: The purpose of this study was to describe the method of delivery, dosage regimens, and outcomes of sedatives administered by extravascular route for imaging procedures in children. METHODS: Medline, Embase, International Pharmaceutical Abstracts, and Cochrane Database of Systematic Reviews were searched using keywords “child”, “midazolam”, “ketamine”, dexmedetomidine”, “fentanyl”, “nitrous oxide”, and “imaging.” Articles evaluating the use of extravascular sedation in children for imaging procedures published in English between 1946 and March 2015 were included. Two authors independently screened each article for inclusion. Reports were excluded if they did not contain sufficient details on dosage regimens and outcomes. RESULTS: Twenty reports representing 1,412 patients ranging in age from 0.33 to 19 years of age were included for analysis. Due to discrepancies in doses and types of analyses, statistical analyses were not performed. Oral midazolam was the most common agent evaluated; other agents included intranasal (IN) ketamine, IN midazolam, IN fentanyl, IN and transmucosal dexmedetomidine, and N2O. Most agents were considered efficacious compared with placebo. CONCLUSIONS: Most agents showed efficacy for sedation during imaging when delivered through an extra-vascular route. Selection of agents should be based on onset time, duration, patient acceptability, recovery time, and adverse events. More robust studies are necessary to determine the optimal agent and route to utilize for imaging procedures when sedation is needed.


1988 ◽  
Vol 10 (1) ◽  
pp. 85-90 ◽  
Author(s):  
Lisa M. Albrecht ◽  
Michael J. Rybak ◽  
Steven C. Boike ◽  
Salvador Pancorbo

1988 ◽  
Vol 10 (1) ◽  
pp. 85-90
Author(s):  
Lisa M. Albrecht ◽  
Michael J. Rybak ◽  
Steven C. Boike ◽  
Salvador Pancorbo

2016 ◽  
Vol 21 (2) ◽  
pp. 155-161 ◽  
Author(s):  
Erin J. McDade ◽  
Jennifer L. Hewlett ◽  
Siby P. Moonnumakal ◽  
Carol J. Baker

OBJECTIVES: The presence of methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis (CF) patients' sputa is associated with a decline in pulmonary function and increased mortality. Vancomycin is the preferred treatment for MRSA pneumonia in children. No published studies have evaluated the vancomycin dose needed to achieve goal vancomycin trough concentrations (VTCs; 15–20 mg/L) in pediatric patients with CF. The primary objective is to determine whether a vancomycin dosage of 60 mg/kg/day achieves a goal VTC in pediatric CF patients. Secondary objectives include determining the average dosage required to reach a goal VTC and the impact of achieving a goal VTC on estimated glomerular filtration rate (eGFR) and pulmonary function. METHODS: A retrospective review of pediatric patients with CF who received vancomycin was conducted. RESULTS: A total of 90 vancomycin treatment courses were analyzed. Standard vancomycin dosing (60 mg/kg/day) achieved goal VTC in 11 courses (12.2%). The mean dosage required to achieve a goal VTC for all courses was 70.6 ± 16.7 mg/kg/day. Patients who achieved goal VTCs were more often older, weighed more, and had higher serum creatinine concentrations at therapy initiation. On average, a dosage of 70.6 mg/kg/day was required to achieve a goal VTC. Despite dosages up to 120 mg/kg/day, no significant changes in renal function occurred. Achieving a goal VTC had no significant impact on eGFR or pulmonary function during therapy. CONCLUSIONS: Vancomycin dosing of 60 mg/kg/day does not reliably achieve a VTC of 15 to 20 mg/L in pediatric CF patients. Younger CF patients may require higher vancomycin doses.


1993 ◽  
Vol 105 (4) ◽  
pp. 705-711 ◽  
Author(s):  
J. Boldt ◽  
C. Knothe ◽  
B. Zickmann ◽  
N. Wege ◽  
F. Dapper ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document